Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Among lecanemab recipients, 17% had brain bleeding, compared with 9% in the placebo group, and 13% had brain swelling, compared with 2% given a placebo.

The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the Clinical Trials on ...

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

Lecanemab, an Alzheimer's drug from Eisai and Biogen, was found to slow the cognitive decline among people with early signs of the disease.

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...